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doi:10.1016/j.jtcvs.2003.11.001622 The Journal of Thoracic and CardioFor years, cardiothoracic surgeons have focused on care factors thataffect outcomes. These efforts have directly resulted in documenteddeclines in mortality and morbidity from major cardiac surgical in-terventions with time, despite an increase in severity of the risk profileof patients coming to surgical intervention.1-3Part of this focus has been to recognize pharmacologic agents that
could affect outcomes, mostly in an adverse manner. At one time, preoperative
aspirin, -blocker, and clopidogrel therapies were relative contraindications to
surgical intervention. Now most patients undergoing coronary artery bypass grafting
(CABG) are on aspirin therapy before the operation, there are compelling data
documenting the benefits of preoperative -blocker therapy4 and perioperative
aspirin therapy5,6 in patients undergoing CABG, and many surgeons administer
clopidogrel before off-pump CABG.
This reversal in our thinking about -blockers4 and to some extent aspirin6
therapy was inspired by large, multicenter observational studies rather than ran-
domized clinical trials. These observational studies have provided scientific data to
reevaluate previous practices in light of newer information. By using sufficiently
large patient populations, controlling for such confounding factors as site and
provider effects, and using statistical techniques such as propensity score analyses,
important information has been obtained that has improved the quality of care. In the
case of -blocker therapy, these findings challenged surgical providers to change not
only their own practice but also the practice of their referring cardiologists.7
In this issue of the Journal, Wijeysundera and colleagues8 have done just such a
reevaluation of the role of calcium-channel blockers (CCBs) as preoperative phar-
macologic therapy in patients undergoing cardiac surgery. Through the years, CCBs
have been investigated in cardiac surgery as cardioplegia additives,9,10 as antiar-
rhythmic agents,11 and as additives to ameliorate vasospasm in radial artery grafts.12
Wijeysundera and colleagues8 raise the question of whether CCBs might convey a
mortality and morbidity benefit in patients undergoing cardiac surgery. The primary
pharmacologic effects of CCBs addressed here are the antianginal and potentially
myoprotective effect of CCBs in patients undergoing the stress of surgical inter-
vention.13 This important study is of interest because it highlights both the good and
the bad related to calcium-channel blockade.
The Good
On the “good” side of the ledger, this is a well-designed observational clinical study
that relies on a robust clinical information system to address the question being
asked. The scientific analysis uses appropriate techniques in the careful evaluation
of these observational data. Wijeysundera and colleagues8 have asked an important
clinical question about a class of cardiovascular drugs that most cardiac surgeons
have not thought much about during the past 5 years. And finally, the study and its
presentation highlight both the importance of these carefully analyzed observational
studies and the limitations in their interpretation. Clearly, this study suggests that
further investigation of the role of preoperative CCBs is warranted.
This was a single-center study, and therefore, as Wijeysundera and colleagues8
point out, site confounding cannot be ruled out as possibly contributing to the
results. For example, the risk-adjusted mortality for the CABG subset was some-vascular Surgery ● March 2004
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Lwhat lower than national US data4; this could be due to a
lower risk study population at this site, differences in the
risk models, or other indeterminate factors that are specific
to the study institution.
The Bad
On the “bad” side of the ledger related to calcium-channel
blockade, it is important to recognize that this study could
not differentiate between different classes of CCBs. The
adverse cardiovascular effects of short-acting, dihydropyri-
dine calcium antagonists are well-documented.14,15 This is a
potentially important confounding issue in light of the rel-
atively diverse negative inotropic effects, conduction sys-
tem effects, and coronary vascular resistance effects of the
different subtypes of these drugs.11,13
Table 1 in the article of Wijeysundera and colleagues8
shows that the percentage of patients in this study receiving
both CCBs and -blocker therapy was significantly higher
than that of those receiving -blocker therapy but not CCBs.
This illustrates an additional difficulty with interpretation of
the study, that of separating preoperative -blocker therapy
effects on outcomes from CCB effects on outcomes. This
study confirms previous studies4,16 documenting the benefit
of preoperative -blocker therapy (Table 3 in the Wijey-
sundera and colleagues8 article). While the Society of Tho-
racic Surgeons database analysis4 did not address CCB use,
the study of Weightman and coworkers16 did not document
CCBs to be of benefit, in contrast to the study of Wijeysun-
dera and colleagues.8 However, preoperative therapy with
CCBs does appear not to lessen a survival benefit in patients
receiving both drugs. In addition, CCBs may provide some
independent benefit (overall data set P value .42, as stated in
Table 4 of the Wijeysundera and colleagues8 article, and
CABG subset P value .44, as stated in Table 6 of the
Wijeysundera and colleagues8 article), although this ques-
tion can only ultimately be answered by a prospective trial.
Furthermore, although the study indicates that CCBs did
not significantly increase morbidity, the odds ratios for
major morbidity outcomes were 1.00 or greater for 8 of 10
morbidities assessed. Clearly, these results from this robust
analysis should be confirmed.
The Issues
The use of CCBs in ischemic heart disease has become
more focused during the past 5 years, in part through the
recognition that some CCBs can be harmful in certain
subsets of patients.13 In addition, the effectiveness of com-
bination therapies for angina control and prevention of
myocardial infarction has been shown,13 and efforts to
improve the use of -blockers in ischemic heart disease
patients have been more successful.17,18 There was a sub-
stantial decline in patients presenting for surgery receiving
CCBs in this study population, presumably reflecting a
The Journal of Thoracidecline in the use of these drugs by the referring cardiolo-
gists. Unlike the situation with preoperative -blocker ther-
apy, if the suggested benefit of CCB therapy in surgical
patients is confirmed, a reversal of this trend on the part of
the cardiology community would be necessary to realize
this benefit in the surgical population.
One important finding from the study is the suggestion
that CCBs may be of benefit in patients undergoing valve
and combined valve and coronary procedures. Because the
benefit of preoperative -blocker therapy has only been
demonstrated for patients, undergoing CABG, the conclu-
sion that a prospective investigation is warranted is timely
and fully supportable.
The current American College of Cardiology and Amer-
ican Heart Association guidelines for management of pa-
tients with chronic stable angina recommend that long-
acting CCBs be used in combination with -blocker therapy
when initial treatment with -blockers is not successful or
as a substitute for -blocker therapy when initial treatment
leads to unacceptable side effects.13 Perhaps these recom-
mendations can provide some structure for identifying pa-
tients in whom preoperative CCB therapy would be poten-
tially beneficial in surgical revascularization and possibly
other cardiac procedures.
Wijeysundera and colleagues8 have readdressed an im-
portant issue in cardiac surgery in their article. Without such
observational analyses, the ability of the cardiac surgical
community to successfully propose randomized trials, par-
ticularly pharmacologic trials, has been limited. Studies
such as this create the opportunity to partner with the
pharmaceutical industry to address the impact of preopera-
tive medications on short-term outcomes. Perhaps more
importantly, the cardiac surgical community needs to ad-
dress the impacts of perioperative and postoperative phar-
macologic therapies on long-term surgical outcomes.19,20
Through these efforts, cardiac surgeons and their care teams
can positively influence both short-term outcomes and the
long-term benefits of our surgical interventions. In turn,
these efforts will greatly facilitate the placement of these
surgical interventions, and their efficacy and appropriate-
ness evaluations, into the larger context of chronic disease
processes.
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